EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reclassification of VUS Using ACMG/AMP Criteria Adapted for Sarcomeric Genes Related to Hypertrophic Cardiomyopathy: Resolution Rate and Considerations

Silvia Caroselli iD, Giulia Corona iD, Marco Fabiani iD, Martina Manzoni iD, Caterina Micolonghi iD, Camilla Savio iD, Aldo Germani iD, Stefania Bragliola iD, Valeria Maselli iD, Speranza Rubattu iD, Beatrice Musumeci iD, Giacomo Tini iD und 4 weitere

Human Mutation · 2025-01 · 2025 (1)

DOI: 10.1155/humu/6500093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, online erschienen am 29.11.2025. Verfasst von Silvia Caroselli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Genetic Testing, Sarcomeres, Genetic Variation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sapienza Università di Roma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Genetic testing is valuable to confirm molecular diagnosis in nearly 60% of cases suspected of hypertrophic cardiomyopathy (HCM). However, the interpretation of variants, especially those of uncertain significance (VUSs), remains challenging for laboratories and clinicians. In April 2024, the ClinGen Cardiomyopathy Variant Curation Expert Panel (VCEP) adapted the ACMG/AMP criteria for eight of the sarcomeric genes ( MYH7 , MYBPC3 , TNNI3 , TNNT2 , TPM1 , ACTC1 , MYL2 , and MYL3 ), providing a refined framework for variant interpretation in these genes. This retrospective study re‐evaluated 69 VUSs identified in 84 HCM patients between 2017 and 2024, aiming to resolve uncertainty and reduce the VUS rate.

Methods

Here, two groups of curators reinterpreted variants with the most recent data using the Cardiomyopathy VCEP specifications until a consensus was reached. To streamline the process, we created a semiautomated decision support tool based on these gene‐specific rules.

Results

The application of the Cardiomyopathy VCEP specifications resulted in the reclassification of 17.4% ( N = 12/69, 95% CI: 10.2%–28.0%) of VUS, whereas the new data alone were not sufficient. Out of the reclassified variants, 91.7% ( N = 11/12) were downgraded to benignity (involving 17 patients), and 8.3% were upgraded to pathogenicity (involving one patient), with a mean reclassification time of 68.3 months, corresponding to 5.7 years. The most applied criteria were related to population (PM2 = 55 % ; BA1/BS1 = 16 % ), bioinformatic prediction (PP3 = 45 % ; BP4 = 25 % ), and critical domains (PM1 = 21 % ). However, most codes suffer from a lack of evidence (segregation data, functional assays, and case‐control studies). When comparing this curation with classifications in public databases, 13.3% ( N = 8/60) and 16.2% ( N = 11/68) of variants listed as having inconclusive significance in ClinVar and CardioClassifier were, respectively, reclassified in this study.

Conclusion

Using gene‐specific ACMG/AMP criteria reduces the rate of VUS, increasing diagnostic yield, and informing clinical management in the context of HCM. Nonetheless, ongoing efforts to generate evidence and promote standardization remain essential to improve variant interpretation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicGenetic TestingSarcomeresGenetic VariationHumansRetrospective StudiesMaleFemaleMutationMiddle AgedGenetic Predisposition to Disease

Autor:innen und Institutionen

  • Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
  • Unità di Genetica Cardiovascolare, Centro Cardiologico Monzino IRCCS, Milan, Italy.
  • UOD Genetica Medica, Sant'Andrea University Hospital, Rome, Italy.
  • Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • UOC Cardiologia, Sant'Andrea University Hospital, Rome, Italy.
  • Angio-Cardio-Neurology Division, IRCCS Neuromed, Pozzilli, Italy.

ORCID-Profile: Silvia Caroselli, Giulia Corona, Marco Fabiani, Martina Manzoni, Caterina Micolonghi, Camilla Savio, Aldo Germani, Stefania Bragliola, Valeria Maselli, Speranza Rubattu, Beatrice Musumeci, Giacomo Tini, Vincenzo Visco, Simona Petrucci, Valeria Novelli, Maria Piane

Förderung

  • Sapienza Università di Roma

Zitieren

APA

Caroselli, S., Corona, G., Fabiani, M., Manzoni, M., Micolonghi, C., Savio, C., Germani, A., Bragliola, S., Maselli, V., Rubattu, S., Musumeci, B., Tini, G., Visco, V., Petrucci, S., Novelli, V., & Piane, M. (2025). Reclassification of VUS Using ACMG/AMP Criteria Adapted for Sarcomeric Genes Related to Hypertrophic Cardiomyopathy: Resolution Rate and Considerations. Human Mutation, 2025(1). https://doi.org/10.1155/humu/6500093

Vancouver

Caroselli S, Corona G, Fabiani M, Manzoni M, Micolonghi C, Savio C, et al. Reclassification of VUS Using ACMG/AMP Criteria Adapted for Sarcomeric Genes Related to Hypertrophic Cardiomyopathy: Resolution Rate and Considerations. Human Mutation. 2025;2025(1). doi:10.1155/humu/6500093

BibTeX
@article{Caroselli2025,
  author = {Caroselli, Silvia and Corona, Giulia and Fabiani, Marco and Manzoni, Martina and Micolonghi, Caterina and Savio, Camilla and Germani, Aldo and Bragliola, Stefania and Maselli, Valeria and Rubattu, Speranza and Musumeci, Beatrice and Tini, Giacomo and Visco, Vincenzo and Petrucci, Simona and Novelli, Valeria and Piane, Maria},
  title = {Reclassification of VUS Using ACMG/AMP Criteria Adapted for Sarcomeric Genes Related to Hypertrophic Cardiomyopathy: Resolution Rate and Considerations},
  journal = {Human Mutation},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/humu/6500093}
}
Kostenlos starten →